Home › Contract awards

Who won: Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Contract awarded
Winning supplierNorthern Care Alliance NHS Foundation Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Sheffield Teaching Hospitals NHS Foundation Trust, Oxford University Hospitals NHS FT, The Newcastle upon Tyne Hospitals NHS Foundation Trust, University Hospitals Southampton, University College London Hospitals NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, KING'S COLLEGE HOSPITAL NHS FT, Great Ormond Street Hospital, Guy's and St Thomas' NHS Foundation Trust, University Hospitals of North Staffordshire NHS Trust, Sheffield Children's NHS Foundation Trust, Leeds Teaching Hopsital NHS Foundation Trust, North Manchester General Hospital, AlderHey Children's NHS FT
BuyerNHS England
Value£1.0m
Award notice22 September 2026
TradeHealth and social care

In short

NHS England awarded "Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service" to Northern Care Alliance NHS Foundation Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Sheffield Teaching Hospitals NHS Foundation Trust, with a value of £1.0m (22 September 2026).

Intention to award the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service. <br/><br/>This is a a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.<br/><br/>Procurement was carried out in Lots for the services as detailed above. Contract values are estimated and will be dependent on number of patients actually treated at each awarded provider.

Get new tenders by email, free

A weekly round-up of new UK public sector contracts. No spam, unsubscribe any time.

Get free tender alerts

More awards from NHS England

Integrated Healthcare Services to HMP Ford & HMP Lewes

£54.7m

Adult Critical Care Transfer Service (ACCTS)

£27.6m
AwardedWon by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUSTNHS England27 October 2026

School Aged Immunisation Services for Kent & Medway and Sussex to NHS England South East.

£17.6m

NHS Vaccination and Immunisation Services

£10,000

NHS Vaccination and Immunisation Services

£10,000
AwardedWon by Hertfordshire Partnership University NHS Foundation TrustNHS England21 October 2026